Severity of bronchiectasis predicts use of and adherence to high frequency chest wall oscillation therapy - Analysis from the United States Bronchiectasis and NTM research registry

High frequency chest wall oscillation (HFCWO) is a form of airway clearance therapy that has been available since the mid-1990s and is routinely used by patients suffering from retained pulmonary secretions. Patients with cystic fibrosis (CF), neuromuscular disease (NMD), and other disorders, including bronchiectasis (BE) and COPD (without BE), are commonly prescribed this therapy. Limited evidence exists describing HFCWO use in the BE population, its impact on long-term management of disease, and the specific patient populations most likely to benefit from this therapy.

Source: Respiratory Medicine - January 31, 2024 Category: Respiratory Medicine Authors: Ashwin Basavaraj, Radmila Choate, Brian C. Becker, Timothy R. Aksamit, Mark L. Metersky, Bronchiectasis and NTM Research Registry Investigators Tags: Original Research Source Type: research